[Adult T-cell leukemia with pleural effusion and infiltration in bilateral anterior chambers]. 2002

Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
First Deparement of Internal Medicine, Ehime University School of Medicine, Ehime.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000867 Anterior Chamber The space in the eye, filled with aqueous humor, bounded anteriorly by the cornea and a small portion of the sclera and posteriorly by a small portion of the ciliary body, the iris, and that part of the crystalline lens which presents through the pupil. (Cline et al., Dictionary of Visual Science, 4th ed, p109) Anterior Chambers,Chamber, Anterior,Chambers, Anterior
D015459 Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa. ATLL,HTLV I Associated T Cell Leukemia Lymphoma,HTLV-Associated Leukemia-Lymphoma,HTLV-I-Associated T-Cell Leukemia-Lymphoma,Human T Lymphotropic Virus Associated Leukemia Lymphoma,Human T Lymphotropic Virus-Associated Leukemia-Lymphoma,Human T-Cell Leukemia-Lymphoma,Leukemia Lymphoma, Adult T Cell,Leukemia Lymphoma, T Cell, Acute, HTLV I Associated,Leukemia, Adult T-Cell,Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated,T Cell Leukemia Lymphoma, HTLV I Associated,T Cell Leukemia, Adult,T-Cell Leukemia, Adult,T-Cell Leukemia-Lymphoma, Adult,T-Cell Leukemia-Lymphoma, HTLV-I-Associated,Adult T-Cell Leukemia,Adult T-Cell Leukemia-Lymphoma,Adult T-Cell Leukemia-Lymphomas,Adult T-Cell Leukemias,HTLV Associated Leukemia Lymphoma,HTLV-Associated Leukemia-Lymphomas,HTLV-I-Associated T-Cell Leukemia-Lymphomas,Human T Cell Leukemia Lymphoma,Human T-Cell Leukemia-Lymphomas,Leukemia, Adult T Cell,Leukemia-Lymphoma, HTLV-Associated,Leukemia-Lymphoma, HTLV-I-Associated T-Cell,Leukemia-Lymphoma, Human T-Cell,Leukemia-Lymphomas, Adult T-Cell,Leukemia-Lymphomas, HTLV-Associated,Leukemia-Lymphomas, HTLV-I-Associated T-Cell,Leukemia-Lymphomas, Human T-Cell,Leukemias, Adult T-Cell,T Cell Leukemia Lymphoma, Adult,T-Cell Leukemia-Lymphoma, Human,T-Cell Leukemia-Lymphomas, Adult,T-Cell Leukemia-Lymphomas, HTLV-I-Associated,T-Cell Leukemia-Lymphomas, Human,T-Cell Leukemias, Adult
D016066 Pleural Effusion, Malignant Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells. Malignant Pleural Effusion,Effusion, Malignant Pleural,Effusions, Malignant Pleural,Malignant Pleural Effusions,Pleural Effusions, Malignant
D017254 Leukemic Infiltration A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site. Infiltration, Leukemic,Infiltrations, Leukemic,Leukemic Infiltrations
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
November 2019, Internal medicine (Tokyo, Japan),
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
August 1995, Internal medicine (Tokyo, Japan),
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
March 1987, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
June 2020, International journal of laboratory hematology,
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
September 2021, Journal of the Egyptian National Cancer Institute,
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
November 2019, Clinical case reports,
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
February 1988, Cancer,
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
October 2002, American journal of ophthalmology,
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
July 1986, The American review of respiratory disease,
Tetsuhiko Nomura, and Ikuya Sakai, and Hiroshi Narumi, and Masaki Yasukawa, and Shigeru Fujita, and Takaaki Hato, and Seiichiro Watanabe
February 1989, Minerva medica,
Copied contents to your clipboard!